| Literature DB >> 28752230 |
Jurgen Sota1, Donato Rigante2, Giuseppe Lopalco3, Bruno Frediani1, Rossella Franceschini4, Mauro Galeazzi1, Florenzo Iannone4, Gian Marco Tosi4, Claudia Fabiani5, Luca Cantarini6.
Abstract
Intraocular inflammation is one of the more relevant complications of Behçet's disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular-BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab. Further large studies are needed to fully elucidate and establish the clinical efficacy of these different tools in the refractory ocular manifestations of BD.Entities:
Keywords: Behçet’s disease; Biologics; Eye disease; Treatment; Uveitis
Mesh：
Substances：
Year: 2017 PMID： 28752230 DOI： 10.1007/s00296-017-3775-5
Source DB: PubMed Journal: Rheumatol Int ISSN： 0172-8172 Impact factor: 2.631